PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
Revenue of PeptiDream Inc. (4587.T)
Revenue in 2023 (TTM): $185.63 M
According to PeptiDream Inc.'s latest financial reports the company's current revenue (TTM) is $185.63 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PeptiDream Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $185.63 M | $111.32 M | $47.69 M | $30.46 M | $19.63 M |
| 2022 | $173.61 M | $117.11 M | $58.32 M | $43.01 M | $48.84 M |
| 2021 | $60.55 M | $45.31 M | $32.39 M | $31.19 M | $23.32 M |
| 2020 | $75.5 M | $61.61 M | $48.89 M | $38.92 M | $28.76 M |
| 2019 | $13.41 M | $4.27 M | $-8,157,742 | $-9,135,767 | $-6,316,008 |
| 2018 | $46.66 M | $35.98 M | $26.52 M | $24.61 M | $17.91 M |
| 2017 | $41.55 M | $30.05 M | $22.14 M | $20.38 M | $15.1 M |
| 2016 | $31.65 M | $22.86 M | $17.36 M | $16.97 M | $12.22 M |
| 2015 | $27.98 M | $20.96 M | $17.4 M | $15.3 M | $10.22 M |
| 2014 | $16 M | $11.33 M | $9.66 M | $9.65 M | $6.49 M |
| 2013 | $5.29 M | $3.26 M | $1.78 M | $1.44 M | $960.16 K |
| 2012 | $4.39 M | $2.66 M | $1.38 M | $1.13 M | $886.89 K |
| 2011 | $1.74 M | $656.75 K | $151.16 K | $-139,312 | $64.46 K |